Creative Planning
SRPT icon

Creative Planning’s Sarepta Therapeutics SRPT Stock Holding History

Creative Planning’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-100
Closed -$1K – 4721
2016
Q2 		$1K Buy
+100
New +$1.85K ﹤0.01% 4209

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Creative Planning's SRPT Position: Q1 2026 in Review

Creative Planning reduced its Sarepta Therapeutics (SRPT) stake by 12% in Q1 2026, selling an estimated $213K and leaving 84,188 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #1965.

Creative Planning first reported a position in SRPT in Q2 2013 and has held it in 51 quarters since. The position peaked at $16.7M in Q2 2019. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Creative Planning held 84,188 shares of Sarepta Therapeutics worth $1.83M as of Q1 2026.
  • Creative Planning sold 11,029 Sarepta Therapeutics shares in Q1 2026, an estimated $213K.
  • Sarepta Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #1965 holding.
  • Creative Planning first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 51 quarters since.
  • Creative Planning's Sarepta Therapeutics position peaked at $16.7M in Q2 2019.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.